Omega Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.04
- Today's High:
- $3.35
- Open Price:
- $3.11
- 52W Low:
- $3.04
- 52W High:
- $11.98
- Prev. Close:
- $3.11
- Volume:
- 35473
Company Statistics
- Market Cap.:
- $208.42 million
- Book Value:
- 1.74
- Revenue TTM:
- $2.60 million
- Operating Margin TTM:
- -4362.9%
- Gross Profit TTM:
- $-74023000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -33.65%
- Return on Equity TTM:
- -88.11%
Company Profile
Omega Therapeutics Inc had its IPO on 2021-07-30 under the ticker symbol OMGA.
The company operates in the Healthcare sector and Biotechnology industry. Omega Therapeutics Inc has a staff strength of 116 employees.
Stock update
Shares of Omega Therapeutics Inc opened at $3.11 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.04 - $3.35, and closed at $3.3.
This is a +6.11% increase from the previous day's closing price.
A total volume of 35,473 shares were traded at the close of the day’s session.
In the last one week, shares of Omega Therapeutics Inc have slipped by -12.7%.
Omega Therapeutics Inc's Key Ratios
Omega Therapeutics Inc has a market cap of $208.42 million, indicating a price to book ratio of 2.2829 and a price to sales ratio of 197.7721.
In the last 12-months Omega Therapeutics Inc’s revenue was $2.60 million with a gross profit of $-74023000 and an EBITDA of $-112127000. The EBITDA ratio measures Omega Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Omega Therapeutics Inc’s operating margin was -4362.9% while its return on assets stood at -33.65% with a return of equity of -88.11%.
In Q2, Omega Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 59.5%.
Omega Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.21 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Omega Therapeutics Inc’s profitability.
Omega Therapeutics Inc stock is trading at a EV to sales ratio of 121.2235 and a EV to EBITDA ratio of -1.9477. Its price to sales ratio in the trailing 12-months stood at 197.7721.
Omega Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $229.02 million
- Total Liabilities
- $33.66 million
- Operating Cash Flow
- $24.05 million
- Capital Expenditure
- $1.03 million
- Dividend Payout Ratio
- 0%
Omega Therapeutics Inc ended 2024 with $229.02 million in total assets and $0 in total liabilities. Its intangible assets were valued at $229.02 million while shareholder equity stood at $95.92 million.
Omega Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $33.66 million in other current liabilities, 55000.00 in common stock, $-292172000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $105.54 million and cash and short-term investments were $112.98 million. The company’s total short-term debt was $19,516,000 while long-term debt stood at $11.62 million.
Omega Therapeutics Inc’s total current assets stands at $124.93 million while long-term investments were $0 and short-term investments were $7.44 million. Its net receivables were $2.86 million compared to accounts payable of $6.33 million and inventory worth $-1661000.00.
In 2024, Omega Therapeutics Inc's operating cash flow was $24.05 million while its capital expenditure stood at $1.03 million.
Comparatively, Omega Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.3
- 52-Week High
- $11.98
- 52-Week Low
- $3.04
- Analyst Target Price
- $11.71
Omega Therapeutics Inc stock is currently trading at $3.3 per share. It touched a 52-week high of $11.98 and a 52-week low of $11.98. Analysts tracking the stock have a 12-month average target price of $11.71.
Its 50-day moving average was $4.3 and 200-day moving average was $6.45 The short ratio stood at 14.48 indicating a short percent outstanding of 0%.
Around 197.1% of the company’s stock are held by insiders while 9148.8% are held by institutions.
Frequently Asked Questions About Omega Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.